🟢 Biomea Fusion is trading 8.62% up in pre-market amid biotech gains; catalyst remains uncertain

Biomea Fusion is trading at $0.80, up +8.62% pre-market, amid a 3.64% pre-market rise in biotech; the move’s catalyst remains uncertain.

• No new company-specific announcement was identified for October 21.
• The latest company release located was October 13 results from the Phase 1 BMF-650 study; that earlier news does not establish a fresh catalyst.
• The available evidence does not establish that the broader biotech rise directly caused the move.